Expanding Therapeutic Options for Pompe Disease: a New Small Molecule Inhibitor of Glycogen Synthase 1 (GYS1) Shows Preclinical Promise in Pompe Disease

Overview

Journal Ann Transl Med

Publisher AME Publishing Company

Date 2025 Jan 16

PMID 39817232

Authors

Rebecca L Koch

Benjamin T Cocanougher

Jeong-A Lim

Nina Raben

Priya S Kishnani

Affiliations

Soon will be listed here.

References

Tang B, Frasinyuk M, Chikwana V, Mahalingan K, Morgan C, Segvich D . Discovery and Development of Small-Molecule Inhibitors of Glycogen Synthase. J Med Chem. 2020; 63(7):3538-3551. PMC: 7233370. DOI: 10.1021/acs.jmedchem.9b01851. View

Savage D, Zhai L, Ravikumar B, Choi C, Snaar J, McGuire A . A prevalent variant in PPP1R3A impairs glycogen synthesis and reduces muscle glycogen content in humans and mice. PLoS Med. 2008; 5(1):e27. PMC: 2214798. DOI: 10.1371/journal.pmed.0050027. View

Li C, Desai A, Gupta P, Dempsey K, Bhambhani V, Hopkin R . Transforming the clinical outcome in CRIM-negative infantile Pompe disease identified via newborn screening: the benefits of early treatment with enzyme replacement therapy and immune tolerance induction. Genet Med. 2021; 23(5):845-855. PMC: 8107133. DOI: 10.1038/s41436-020-01080-y. View

Raben N, Nagaraju K, Lee E, Kessler P, Byrne B, Lee L . Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II. J Biol Chem. 1998; 273(30):19086-92. DOI: 10.1074/jbc.273.30.19086. View

Douillard-Guilloux G, Raben N, Takikita S, Batista L, Caillaud C, Richard E . Modulation of glycogen synthesis by RNA interference: towards a new therapeutic approach for glycogenosis type II. Hum Mol Genet. 2008; 17(24):3876-86. DOI: 10.1093/hmg/ddn290. View

van der Ploeg A, Carlier P, Carlier R, Kissel J, Schoser B, Wenninger S . Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study. Mol Genet Metab. 2016; 119(1-2):115-23. DOI: 10.1016/j.ymgme.2016.05.013. View

Orth M, Mundegar R . Effect of acid maltase deficiency on the endosomal/lysosomal system and glucose transporter 4. Neuromuscul Disord. 2002; 13(1):49-54. DOI: 10.1016/s0960-8966(02)00186-4. View

Douillard-Guilloux G, Raben N, Takikita S, Ferry A, Vignaud A, Guillet-Deniau I . Restoration of muscle functionality by genetic suppression of glycogen synthesis in a murine model of Pompe disease. Hum Mol Genet. 2009; 19(4):684-96. PMC: 6281383. DOI: 10.1093/hmg/ddp535. View

Cohen J, Chakraborty P, Fung-Kee-Fung K, Schwab M, Bali D, Young S . In Utero Enzyme-Replacement Therapy for Infantile-Onset Pompe's Disease. N Engl J Med. 2022; 387(23):2150-2158. PMC: 10794051. DOI: 10.1056/NEJMoa2200587. View

10.

Mackenbach M, Willemse E, van den Dorpel J, van der Beek N, Diaz-Manera J, Rizopoulos D . Neurofilament Light and Its Association With CNS Involvement in Patients With Classic Infantile Pompe Disease. Neurology. 2023; 101(6):e594-e601. PMC: 10424841. DOI: 10.1212/WNL.0000000000207482. View

11.

Meena N, Ralston E, Raben N, Puertollano R . Enzyme Replacement Therapy Can Reverse Pathogenic Cascade in Pompe Disease. Mol Ther Methods Clin Dev. 2020; 18:199-214. PMC: 7334420. DOI: 10.1016/j.omtm.2020.05.026. View

12.

Kollberg G, Tulinius M, Gilljam T, Ostman-Smith I, Forsander G, Jotorp P . Cardiomyopathy and exercise intolerance in muscle glycogen storage disease 0. N Engl J Med. 2007; 357(15):1507-14. DOI: 10.1056/NEJMoa066691. View

13.

Fastman N, Liu Y, Ramanan V, Merritt H, Ambing E, DePaoli-Roach A . The structural mechanism of human glycogen synthesis by the GYS1-GYG1 complex. Cell Rep. 2022; 40(1):111041. DOI: 10.1016/j.celrep.2022.111041. View

14.

McCorvie T, Loria P, Tu M, Han S, Shrestha L, Froese D . Molecular basis for the regulation of human glycogen synthase by phosphorylation and glucose-6-phosphate. Nat Struct Mol Biol. 2022; 29(7):628-638. PMC: 9287172. DOI: 10.1038/s41594-022-00799-3. View

15.

Marr L, Biswas D, Daly L, Browning C, Vial S, Maskell D . Mechanism of glycogen synthase inactivation and interaction with glycogenin. Nat Commun. 2022; 13(1):3372. PMC: 9188544. DOI: 10.1038/s41467-022-31109-6. View

16.

Kenney-Jung D, Korlimarla A, Spiridigliozzi G, Wiggins W, Malinzak M, Nichting G . Severe CNS involvement in a subset of long-term treated children with infantile-onset Pompe disease. Mol Genet Metab. 2024; 141(2):108119. PMC: 11080415. DOI: 10.1016/j.ymgme.2023.108119. View

17.

Canibano-Fraile R, Harlaar L, Dos Santos C, Hoogeveen-Westerveld M, Demmers J, Snijders T . Lysosomal glycogen accumulation in Pompe disease results in disturbed cytoplasmic glycogen metabolism. J Inherit Metab Dis. 2022; 46(1):101-115. PMC: 10092494. DOI: 10.1002/jimd.12560. View

18.

Taylor K, Meyers E, Phipps M, Kishnani P, Cheng S, Scheule R . Dysregulation of multiple facets of glycogen metabolism in a murine model of Pompe disease. PLoS One. 2013; 8(2):e56181. PMC: 3572993. DOI: 10.1371/journal.pone.0056181. View

19.

Xu S, Lun Y, Frascella M, Garcia A, Soska R, Nair A . Improved efficacy of a next-generation ERT in murine Pompe disease. JCI Insight. 2019; 4(5). PMC: 6483515. DOI: 10.1172/jci.insight.125358. View

20.

Ullman J, Mellem K, Xi Y, Ramanan V, Merritt H, Choy R . Small-molecule inhibition of glycogen synthase 1 for the treatment of Pompe disease and other glycogen storage disorders. Sci Transl Med. 2024; 16(730):eadf1691. PMC: 10962247. DOI: 10.1126/scitranslmed.adf1691. View